

Jay S Schneider

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4581068/jay-s-schneider-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

129
papers

6,199
citations

43
h-index

74
g-index

130
ext. papers

6,822
ext. citations

5.1
avg. IF

5.98
L-index

#	Paper	IF	Citations
129	Current concepts in treating mild cognitive impairment in Parkinson's disease. <i>Neuropharmacology</i> , 2022 , 203, 108880	5.5	0
128	GM1 ganglioside modifies microglial and neuroinflammatory responses to α -synuclein in the rat AAV-A53T α -synuclein model of Parkinson's disease.. <i>Molecular and Cellular Neurosciences</i> , 2022 , 103729	4.8	
127	A critical role for GM1 ganglioside in the pathophysiology and potential treatment of Parkinson's disease. <i>Glycoconjugate Journal</i> , 2021 , 1	3	3
126	A novel dopamine D3R agonist SK609 with norepinephrine transporter inhibition promotes improvement in cognitive task performance in rodent and non-human primate models of Parkinson's disease. <i>Experimental Neurology</i> , 2021 , 335, 113514	5.7	10
125	NYX-458 Improves Cognitive Performance in a Primate Parkinson's Disease Model. <i>Movement Disorders</i> , 2020 , 35, 640-649	7	9
124	Low-level lead exposure impairs fronto-executive functions: A call to update the DSM-5 with lead poisoning as a neurodevelopmental disorder.. <i>Psychology and Neuroscience</i> , 2020 , 13, 299-325	1.9	5
123	Gangliosides: Treatment Avenues in Neurodegenerative Disease. <i>Frontiers in Neurology</i> , 2019 , 10, 859	4.1	49
122	GM1 Ganglioside Modifies α -Synuclein Toxicity and is Neuroprotective in a Rat α -Synuclein Model of Parkinson's Disease. <i>Scientific Reports</i> , 2019 , 9, 8362	4.9	28
121	The attention set-shifting test is sensitive for revealing sex-based impairments in executive functions following developmental lead exposure in rats. <i>Behavioural Brain Research</i> , 2019 , 366, 126-134	2.4	9
120	PET imaging of dopamine release in the frontal cortex of manganese-exposed non-human primates. <i>Journal of Neurochemistry</i> , 2019 , 150, 188-201	6	6
119	siRNA-mediated knockdown of B3GALT4 decreases GM1 ganglioside expression and enhances vulnerability for neurodegeneration. <i>Molecular and Cellular Neurosciences</i> , 2019 , 95, 25-30	4.8	5
118	Post-translational histone modifications and their interaction with sex influence normal brain development and elaboration of neuropsychiatric disorders. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019 , 1865, 1968-1981	6.9	7
117	The Tyrosine Phosphatase STEP Is Involved in Age-Related Memory Decline. <i>Current Biology</i> , 2018 , 28, 1079-1089.e4	6.3	17
116	Effects of developmental lead exposure on the hippocampal methylome: Influences of sex and timing and level of exposure. <i>Toxicology Letters</i> , 2018 , 290, 63-72	4.4	21
115	Developmental Lead Exposure and Prenatal Stress Result in Sex-Specific Reprogramming of Adult Stress Physiology and Epigenetic Profiles in Brain. <i>Toxicological Sciences</i> , 2018 , 163, 478-489	4.4	25
114	Sex-Dependent Effects of Developmental Lead Exposure on the Brain. <i>Frontiers in Genetics</i> , 2018 , 9, 89	4.5	29
113	Altered expression of genes involved in ganglioside biosynthesis in substantia nigra neurons in Parkinson's disease. <i>PLoS ONE</i> , 2018 , 13, e0199189	3.7	34

112	Different Behavioral Experiences Produce Distinctive Parallel Changes in, and Correlate With, Frontal Cortex and Hippocampal Global Post-translational Histone Levels. <i>Frontiers in Integrative Neuroscience</i> , 2018 , 12, 29	3.2	6
111	Sex-Related Abnormalities in Substantia Nigra Lipids in Parkinson's Disease. <i>ASN Neuro</i> , 2018 , 10, 1759091-18781889	3.5	49
110	Caffeine, creatine, GRIN2A and Parkinson's disease progression. <i>Journal of the Neurological Sciences</i> , 2017 , 375, 355-359	3.2	17
109	Developmental Lead and/or Prenatal Stress Exposures Followed by Different Types of Behavioral Experience Result in the Divergence of Brain Epigenetic Profiles in a Sex, Brain Region, and Time-Dependent Manner: Implications for Neurotoxicology. <i>Current Opinion in Toxicology</i> , 2017 , 6, 60-70	4.4	6
108	Sex- and brain region- specific effects of prenatal stress and lead exposure on permissive and repressive post-translational histone modifications from embryonic development through adulthood. <i>NeuroToxicology</i> , 2017 , 62, 207-217	4.4	23
107	Strain specific effects of low level lead exposure on associative learning and memory in rats. <i>NeuroToxicology</i> , 2017 , 62, 186-191	4.4	12
106	Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1. <i>Parkinsonism and Related Disorders</i> , 2016 , 33, 127-133	3.6	6
105	Effects of low level lead exposure on associative learning and memory in the rat: Influences of sex and developmental timing of exposure. <i>Toxicology Letters</i> , 2016 , 246, 57-64	4.4	27
104	Epigenetic Mechanisms of Adverse Neurodevelopment in Response to Lead Exposure and Prenatal Stress and the Combination: The Road Ahead 2016 , 251-277		
103	Sex-dependent effects of lead and prenatal stress on post-translational histone modifications in frontal cortex and hippocampus in the early postnatal brain. <i>NeuroToxicology</i> , 2016 , 54, 65-71	4.4	35
102	GM1 ganglioside in Parkinson's disease: Pilot study of effects on dopamine transporter binding. <i>Journal of the Neurological Sciences</i> , 2015 , 356, 118-23	3.2	32
101	Effects of chronic manganese exposure on attention and working memory in non-human primates. <i>NeuroToxicology</i> , 2015 , 48, 217-22	4.4	18
100	Relationship between Motor Symptoms, Cognition, and Demographic Characteristics in Treated Mild/Moderate Parkinson's Disease. <i>PLoS ONE</i> , 2015 , 10, e0123231	3.7	30
99	Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 584-93	27.4	153
98	Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine. <i>Clinical Neuropharmacology</i> , 2015 , 38, 163-9	1.4	18
97	Intraventricular Sialidase Administration Enhances GM1 Ganglioside Expression and Is Partially Neuroprotective in a Mouse Model of Parkinson's Disease. <i>PLoS ONE</i> , 2015 , 10, e0143351	3.7	27
96	The neurobiological basis of cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2014 , 29, 634-50	7	209
95	Genetic diversity influences the response of the brain to developmental lead exposure. <i>Toxicological Sciences</i> , 2014 , 141, 29-43	4.4	13

94	Retinal pathology detected by optical coherence tomography in an animal model of Parkinson's disease. <i>Movement Disorders</i> , 2014 , 29, 1547-51	7	10
93	No sex differences in use of dopaminergic medication in early Parkinson disease in the US and Canada - baseline findings of a multicenter trial. <i>PLoS ONE</i> , 2014 , 9, e112287	3.7	9
92	Gangliosides and glycolipids in neurodegenerative disorders. <i>Advances in Neurobiology</i> , 2014 , 9, 449-61	2.1	12
91	Manganese exposure induces α -synuclein aggregation in the frontal cortex of non-human primates. <i>Toxicology Letters</i> , 2013 , 217, 177-83	4.4	49
90	Rearing environment, sex and developmental lead exposure modify gene expression in the hippocampus of behaviorally naïve animals. <i>Neurochemistry International</i> , 2013 , 62, 510-20	4.4	16
89	Chronic manganese exposure impairs visuospatial associative learning in non-human primates. <i>Toxicology Letters</i> , 2013 , 221, 146-51	4.4	25
88	Influence of developmental lead exposure on expression of DNA methyltransferases and methyl cytosine-binding proteins in hippocampus. <i>Toxicology Letters</i> , 2013 , 217, 75-81	4.4	70
87	Effects of memantine and galantamine on cognitive performance in aged rhesus macaques. <i>Neurobiology of Aging</i> , 2013 , 34, 1126-32	5.6	13
86	Levodopa improves motor deficits but can further disrupt cognition in a macaque Parkinson model. <i>Movement Disorders</i> , 2013 , 28, 663-7	7	27
85	A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients. <i>Journal of the Neurological Sciences</i> , 2013 , 324, 140-8	3.2	99
84	Sex and rearing condition modify the effects of perinatal lead exposure on learning and memory. <i>NeuroToxicology</i> , 2012 , 33, 985-95	4.4	22
83	Effects of developmental lead exposure on the hippocampal transcriptome: influences of sex, developmental period, and lead exposure level. <i>Toxicological Sciences</i> , 2012 , 129, 108-25	4.4	33
82	Impaired spatial working memory learning and performance in normal aged rhesus monkeys. <i>Behavioural Brain Research</i> , 2012 , 232, 287-93	3.4	4
81	Differential effect of postnatal lead exposure on gene expression in the hippocampus and frontal cortex. <i>Journal of Molecular Neuroscience</i> , 2012 , 47, 76-88	3.3	24
80	Attention, executive functioning and memory in normal aged rhesus monkeys. <i>Behavioural Brain Research</i> , 2011 , 219, 23-30	3.4	24
79	Manganese exposure induces microglia activation and dystrophy in the substantia nigra of non-human primates. <i>NeuroToxicology</i> , 2011 , 32, 215-26	4.4	59
78	Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. <i>Neuroscience</i> , 2011 , 194, 189-94	3.9	78
77	Effects of the alpha-2 adrenoceptor agonist guanfacine on attention and working memory in aged non-human primates. <i>European Journal of Neuroscience</i> , 2011 , 34, 1018-22	3.5	18

76	Sex-based differences in gene expression in hippocampus following postnatal lead exposure. <i>Toxicology and Applied Pharmacology</i> , 2011 , 256, 179-90	4.6	25
75	The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures. <i>International Journal of Neuropsychopharmacology</i> , 2010 , 13, 1035-51	5.8	59
74	GM1 ganglioside in Parkinson's disease: Results of a five year open study. <i>Journal of the Neurological Sciences</i> , 2010 , 292, 45-51	3.2	107
73	Clonidine improves attentional and memory components of delayed response performance in a model of early Parkinsonism. <i>Behavioural Brain Research</i> , 2010 , 211, 236-9	3.4	14
72	Predictors of cognitive outcomes in early Parkinson disease patients: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. <i>Parkinsonism and Related Disorders</i> , 2010 , 16, 507-12	3.6	10
71	Protection of dopaminergic cells from MPP+-mediated toxicity by histone deacetylase inhibition. <i>Brain Research</i> , 2010 , 1354, 172-8	3.7	72
70	Effects of chronic manganese exposure on glutamatergic and GABAergic neurotransmitter markers in the nonhuman primate brain. <i>Toxicological Sciences</i> , 2009 , 111, 131-9	4.4	35
69	Effects of chronic manganese exposure on working memory in non-human primates. <i>Brain Research</i> , 2009 , 1258, 86-95	3.7	60
68	Interaction between nicotinic and dopaminergic therapies on cognition in a chronic Parkinson model. <i>Brain Research</i> , 2009 , 1262, 109-14	3.7	37
67	Increased APLP1 expression and neurodegeneration in the frontal cortex of manganese-exposed non-human primates. <i>Journal of Neurochemistry</i> , 2008 , 105, 1948-59	6	96
66	Impairment of nigrostriatal dopamine neurotransmission by manganese is mediated by pre-synaptic mechanism(s): implications to manganese-induced parkinsonism. <i>Journal of Neurochemistry</i> , 2008 , 107, 1236-47	6	121
65	Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism. <i>European Journal of Neuroscience</i> , 2008 , 28, 610-7	3.5	50
64	Postnatal lead exposure alters expression of forebrain p75 and TrkA nerve growth factor receptors. <i>Brain Research</i> , 2008 , 1195, 113-9	3.7	9
63	Behavioral persistence deficit in Parkinson's disease patients. <i>European Journal of Neurology</i> , 2007 , 14, 300-4	6	18
62	Manganese: recent advances in understanding its transport and neurotoxicity. <i>Toxicology and Applied Pharmacology</i> , 2007 , 221, 131-47	4.6	461
61	Beta2* and beta4* nicotinic acetylcholine receptor expression changes with progressive parkinsonism in non-human primates. <i>Neurobiology of Disease</i> , 2007 , 27, 312-9	7.5	5
60	Postnatal lead poisoning impairs behavioral recovery following brain damage. <i>NeuroToxicology</i> , 2007 , 28, 1153-7	4.4	20
59	The synthetic ceramide analog L-PDMP partially protects striatal dopamine levels but does not promote dopamine neuron survival in murine models of parkinsonism. <i>Brain Research</i> , 2006 , 1099, 199-205	3.7	10

58	Effects of chronic manganese exposure on cognitive and motor functioning in non-human primates. <i>Brain Research</i> , 2006 , 1118, 222-31	3.7	80
57	Evidence for cortical dysfunction and widespread manganese accumulation in the nonhuman primate brain following chronic manganese exposure: a 1H-MRS and MRI study. <i>Toxicological Sciences</i> , 2006 , 94, 351-8	4.4	93
56	Adverse effects of childhood lead poisoning: the clinical neuropsychological perspective. <i>Environmental Research</i> , 2006 , 100, 284-93	7.9	65
55	Nigrostriatal dopamine system dysfunction and subtle motor deficits in manganese-exposed non-human primates. <i>Experimental Neurology</i> , 2006 , 202, 381-90	5.7	150
54	Modeling Cognitive Deficits Associated with Parkinsonism in the Chronic-Low-Dose MPTP-Treated Monkey. <i>Frontiers in Neuroscience</i> , 2006 , 169-180		3
53	Effects of nicotinic therapies on attention and executive functions in chronic low-dose MPTP-treated monkeys. <i>European Journal of Neuroscience</i> , 2006 , 24, 2098-104	3.5	25
52	Neuroprotection in Parkinson models varies with toxin administration protocol. <i>European Journal of Neuroscience</i> , 2006 , 24, 3174-82	3.5	53
51	Inhibition of progenitor cell proliferation in the dentate gyrus of rats following post-weaning lead exposure. <i>NeuroToxicology</i> , 2005 , 26, 141-5	4.4	20
50	Attention and executive function deficits in chronic low-dose MPTP-treated non-human primates. <i>European Journal of Neuroscience</i> , 2004 , 20, 1371-8	3.5	80
49	Modulation of ATP levels alters the mode of hydrogen peroxide-induced cell death in primary cortical cultures: effects of putative neuroprotective agents. <i>Brain Research</i> , 2004 , 997, 79-88	3.7	17
48	Attentional cueing reverses deficits in spatial working memory task performance in chronic low dose MPTP-treated monkeys. <i>Behavioural Brain Research</i> , 2004 , 152, 259-62	3.4	22
47	Effects of lead exposure on proliferation and differentiation of neural stem cells derived from different regions of embryonic rat brain. <i>NeuroToxicology</i> , 2004 , 25, 1001-12	4.4	48
46	Effects of low-level lead exposure on cell survival and neurite length in primary mesencephalic cultures. <i>Neurotoxicology and Teratology</i> , 2003 , 25, 555-9	3.9	28
45	Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms. <i>Brain Research</i> , 2003 , 990, 38-44	3.7	40
44	Experimental parkinsonism is associated with increased pallidal GAD gene expression and is reversed by site-directed antisense gene therapy. <i>Movement Disorders</i> , 2003 , 18, 32-40	7	13
43	The subtype-selective nicotinic acetylcholine receptor agonist SIB-1553A improves both attention and memory components of a spatial working memory task in chronic low dose 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003 , 306, 401-6	4.7	40
42	Lead neurotoxicity in children: basic mechanisms and clinical correlates. <i>Brain</i> , 2003 , 126, 5-19	11.2	726
41	Effects of the prolyl endopeptidase inhibitor S 17092 on cognitive deficits in chronic low dose MPTP-treated monkeys. <i>Neuropsychopharmacology</i> , 2002 , 26, 176-82	8.7	58

40	Enriched environment during development is protective against lead-induced neurotoxicity. <i>Brain Research</i> , 2001 , 896, 48-55	3.7	92
39	Neuroprotective effects of pramipexole in young and aged MPTP-treated mice. <i>Brain Research</i> , 2001 , 905, 44-53	3.7	49
38	Expression of striatal preprotachykinin mRNA in symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys is related to parkinsonian motor signs. <i>Journal of Neuroscience</i> , 2001 , 21, 4901-7	6.6	17
37	Effects of GM1 ganglioside treatment on pre- and postsynaptic dopaminergic markers in the striatum of parkinsonian monkeys. <i>Synapse</i> , 2000 , 36, 120-8	2.4	26
36	Effects of the partial glycine agonist D-cycloserine on cognitive functioning in chronic low dose MPTP-treated monkeys. <i>Brain Research</i> , 2000 , 860, 190-4	3.7	40
35	Striatal preproenkephalin gene expression is upregulated in acute but not chronic parkinsonian monkeys: implications for the contribution of the indirect striatopallidal circuit to parkinsonian symptomatology. <i>Journal of Neuroscience</i> , 1999 , 19, 6643-9	6.6	47
34	Differential regulation of striatal dopamine D(1) and D(2) receptors in acute and chronic parkinsonian monkeys. <i>Brain Research</i> , 1999 , 847, 134-8	3.7	16
33	Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1999 , 290, 731-9	4.7	61
32	GM1 ganglioside in the treatment of Parkinson's disease. <i>Annals of the New York Academy of Sciences</i> , 1998 , 845, 363-73	6.5	34
31	Differential recovery of sensorimotor function in GM1 ganglioside-treated vs. spontaneously recovered MPTP-treated cats: partial striatal dopaminergic reinnervation vs. neurochemical compensation. <i>Brain Research</i> , 1998 , 813, 82-7	3.7	13
30	Effects of the nicotinic acetylcholine receptor agonist SIB-1508Y on object retrieval performance in MPTP-treated monkeys: comparison with levodopa treatment. <i>Annals of Neurology</i> , 1998 , 43, 311-7	9.4	55
29	Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys. <i>Movement Disorders</i> , 1998 , 13, 637-42	7	56
28	Parkinson's disease: improved function with GM1 ganglioside treatment in a randomized placebo-controlled study. <i>Neurology</i> , 1998 , 50, 1630-6	6.5	66
27	Chronic neuroleptic treatment alters expression of glial glutamate transporter GLT-1 mRNA in the striatum. <i>NeuroReport</i> , 1998 , 9, 133-6	1.7	55
26	Differential effects of GDNF treatment on rotational asymmetry, skilled forelimb use deficits and sensory neglect in unilateral 6-OHDA-lesioned rats. <i>Restorative Neurology and Neuroscience</i> , 1998 , 13, 205-12	2.8	8
25	Preservation of autoreceptor-mediated increases in dopamine synthesis in aged mice with experimentally-induced parkinsonism. <i>Neuroscience Letters</i> , 1997 , 222, 138-40	3.3	1
24	The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys. <i>Movement Disorders</i> , 1997 , 12, 148-58	7	52
23	Alterations in dopamine uptake sites and D1 and D2 receptors in cats symptomatic for and recovered from experimental parkinsonism. <i>Synapse</i> , 1995 , 19, 46-55	2.4	28

22	Differential recovery of volitional motor function, lateralized cognitive function, dopamine agonist-induced rotation and dopaminergic parameters in monkeys made hemi-parkinsonian by intracarotid MPTP infusion. <i>Brain Research</i> , 1995 , 672, 112-7	3-7	32
21	Enhanced restoration of striatal dopamine concentrations by combined GM1 ganglioside and neurotrophic factor treatments. <i>Brain Research</i> , 1995 , 674, 260-4	3-7	14
20	Cognitive deficits precede motor deficits in a slowly progressing model of parkinsonism in the monkey. <i>Experimental Neurology</i> , 1995 , 4, 245-55		86
19	GM1 ganglioside treatment of Parkinson's disease: an open pilot study of safety and efficacy. <i>Neurology</i> , 1995 , 45, 1149-54	6.5	43
18	GM1 ganglioside rescues substantia nigra pars compacta neurons and increases dopamine synthesis in residual nigrostriatal dopaminergic neurons in MPTP-treated mice. <i>Journal of Neuroscience Research</i> , 1995 , 42, 117-23	4.4	38
17	Effects of dihydrexidine, a full dopamine D-1 receptor agonist, on delayed response performance in chronic low dose MPTP-treated monkeys. <i>Brain Research</i> , 1994 , 663, 140-4	3-7	61
16	GM1 ganglioside treatment partially reverses the nigrostriatal dopamine defect in the weaver mutant mouse. <i>Brain Research</i> , 1994 , 636, 353-6	3-7	6
15	GM1 ganglioside partially rescues cultured dopaminergic neurons from MPP(+)-induced damage: dependence on initial damage and time of treatment. <i>Brain Research</i> , 1994 , 640, 308-15	3-7	24
14	Task persistence and learning ability in normal and chronic low dose MPTP-treated monkeys. <i>Behavioural Brain Research</i> , 1994 , 60, 115-24	3-4	38
13	The Therapeutic Role of Gangliosides in Neurological Disorders. <i>CNS Drugs</i> , 1994 , 1, 213-22	6.7	10
12	Delayed matching-to-sample, object retrieval, and discrimination reversal deficits in chronic low dose MPTP-treated monkeys. <i>Brain Research</i> , 1993 , 615, 351-4	3-7	78
11	MPTP-induced parkinsonism: acceleration of biochemical and behavioral recovery by GM1 ganglioside treatment. <i>Journal of Neuroscience Research</i> , 1992 , 31, 112-9	4.4	34
10	Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment. <i>Science</i> , 1992 , 256, 843-6	33-3	157
9	Chronic low-dose MPTP in nonhuman primates: a possible model for attention deficit disorder. <i>Journal of Child Neurology</i> , 1991 , 6 Suppl, S82-9	2.5	29
8	Responses of striatal neurons to peripheral sensory stimulation in symptomatic MPTP-exposed cats. <i>Brain Research</i> , 1991 , 544, 297-302	3-7	44
7	Erratum. <i>Science</i> , 1991 , 251, 1162	33-3	
6	GABAergic Pathway from Zona Incerta to Neocortex: Clarification. <i>Science</i> , 1991 , 251, 1162-1162	33-3	1
5	Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys. <i>Brain Research</i> , 1990 , 519, 122-8	3-7	209

4	Chronic exposure to low doses of MPTP. II. Neurochemical and pathological consequences in cognitively-impaired, motor asymptomatic monkeys. <i>Brain Research</i> , 1990 , 534, 25-36	3-7	94
3	Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage. <i>Pharmacology Biochemistry and Behavior</i> , 1989 , 34, 193-6	3-9	90
2	Anatomical evidence of the projection of pontine omnipause neurons to midbrain regions controlling vertical eye movements. <i>Journal of Comparative Neurology</i> , 1989 , 289, 610-25	3-4	22
1	GM1 ganglioside treatment promotes recovery of striatal dopamine concentrations in the mouse model of MPTP-induced parkinsonism. <i>Experimental Neurology</i> , 1989 , 105, 177-83	5-7	62